BioCentury on BioBusiness,
Emerging Company Profile
Locus: Atom-by-atom drug design
Monday, October 30, 2000
The drug discovery process would be completely transformed if small molecule therapeutics could be designed against proteins in a matter of weeks. Locus Discovery Inc. has licensed computational chemogenomics technology from Sarnoff Research Institute that the company says has successfully predicted the binding site and/or correct chemistries of a dozen known proteins in a few weeks.
The company's technology starts with the structure of a protein - it does not require knowledge of its normal function or ligand - and uses computer modeling to design a small molecule inhibitor or agonist. "We start with the 3-D structure with a resolution of 3 angstroms or better from x-ray crystallography or NMR," said President and CEO Nicholas Landekic. "We don't need to know the binding site or see the ligand bound to the protein. For it to work, all you need to have is the valid structure of the active protein."
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]